Articles
All vignettes
- Aguiar_2021_ustekinumab
- Bajaj_2017_nivolumab
- Trastuzumab emtansine (T-DM1) preclinical mechanistic DAR PK model (Bender 2014)
- Trastuzumab emtansine (T-DM1) preclinical reduced PK model (Bender 2014)
- Berends_2019_infliximab
- Brillac_2025_isatuximab
- Budha_2023_tislelizumab
- CarlssonPetri_2021_liraglutide
- Castro-Surez_2020_nimotuzumab
- Chen_2020_luspatercept
- Chen_2022_guselkumab
- Cheng_2026_immunoglobulin
- Chua_2025_mirikizumab
- Cirincione_2017_exenatide
- Clegg_2024_nirsevimab
- Creating a model library
- Diao_2016_daclizumab_cd25
- Diao_2016_daclizumab_cd56bright
- Diao_2016_daclizumab_treg
- Faelens_2021_infliximab
- Farrell_2012_farletuzumab
- Fasanmade_2009_infliximab
- Fau_2020_isatuximab
- Fiedler-Kelly_2019_fremanezumab
- FiedlerKelly_2020_fremanezumab_cm
- FiedlerKelly_2020_fremanezumab_em
- Frey_2010_tocilizumab
- Frey_2013_tocilizumab
- Gandhi_2021_abatacept
- Trontinemab and gantenerumab PK in plasma and brain (Grimm 2023)
- Gupta_2016_amatuximab
- Hanzel_2021_infliximab
- Hayashi_2007_omalizumab
- Datopotamab deruxtecan ADC + DXd coupled population PK model (Hong 2025)
- Hood_2021_medi7836
- Hu_2014_bapineuzumab
- Hu_2026_clesrovimab
- Hua_2015_anrukinzumab
- Huang_2017_vrc01
- Hwang_2022_tremelimumab
- Hwang_2023_monalizumab
- Ide_2020_elotuzumab
- Jackson_2022_ixekizumab
- Kielbasa_2020_galcanezumab
- Koopman_2023_factorix
- Kotani_2022_astegolimab
- Kovalenko_2016_dupilumab
- Kovalenko_2020_dupilumab
- Kuchimanchi_2018_evolocumab
- Kuchimanchi_2024_dostarlimab
- Kyhl_2016_nalmefene
- Intrathecal trastuzumab in HER2+ breast cancer LMC (Le Tilly 2021)
- Brentuximab vedotin ADC + MMAE coupled population PK model (Li 2017)
- Li_2019_abatacept
- Lin_2024_casirivimab
- Lin_2024_pozelimab
- List of models
- Lon_2013_abatacept
- Long_2017_necitumumab
- Lu_2014_trastuzumabemtansine
- Polatuzumab vedotin acMMAE + MMAE integrated population PK model (Lu 2019)
- Patritumab deruxtecan (HER3-DXd) ADC + DXd coupled population PK model (Lu 2022)
- Ma_2020_sarilumab_anc
- Ma_2020_sarilumab_das28crp
- Markov modeling
- Marquez-Megias_2023_adalimumab
- Martinez_2019_alirocumab
- Masters_2022_avelumab
- Melhem_2022_dostarlimab
- Mo_2018_olaratumab
- Moein_2022_etrolizumab
- Mould_2007_alemtuzumab
- Mulyukov_2018_ranibizumab
- Narwal_2013_sifalimumab
- Nestorov_2014_factorviii
- Ngo_2020_HL2351
- Nikanjam_2019_siltuximab
- Ogasawara_2020_durvalumab
- Okada_2025_rocatinlimab
- Othman_2014_daclizumab
- Papachristos_2020_bevacizumab_pk
- Papachristos_2020_bevacizumab_pkpd
- Papachristos_2020_bevacizumab_qss
- Papathanasiou_2025_belantamab
- PerezRuixo_2025_posdinemab
- Petrov_2024_romiplostim
- PK_2cmt_mAb_Davda_2014
- Pouzin_2022_tusamitamab
- Quartino_2019_trastuzumab
- Robbie_2012_palivizumab
- Rosario_2015_vedolizumab
- Sanghavi_2020_ipilimumab
- Sathe_2024_sacituzumab
- Soehoel_2022_tralokinumab
- Suleiman_2019_risankizumab
- Suri_2018_brentuximab
- Takahashi_2023_abatacept
- Takeuchi_2023_ozoralizumab
- Thakre_2022_risankizumab
- Timmermann_2019_brodalumab
- Tiraboschi_2025_amlitelimab
- TMDD archetypes: full, QSS, and Michaelis-Menten approximations
- Toukam_2025_biib107
- Valenzuela_2025_nipocalimab
- Wade_2015_certolizumab
- Wang_2017_benralizumab
- Wang_2020_ontamalimab
- Wang_2024_sugemalimab
- Wojciechowski_2022_domagrozumab
- Wu_2024_inotuzumab
- Xie_2019_agomelatine
- Xu_2011_sirukumab
- Xu_2019_sarilumab
- Yamada_2025_zolbetuximab
- Yang_2021_cemiplimab
- Axatilimab semimechanistic PK/PD model (Yang 2024)
- Yao_2018_guselkumab
- Yin_2021_trastuzumabDeruxtecan
- Yu_2022_ofatumumab
- Zhang_2019_nivolumab
- Zheng_2016_sifalimumab
- Zhong_2026_abatacept
- Zhou_2021_belimumab
- Zhou_2025_brentuximab
- Zhu_2017_lebrikizumab